{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:16:25Z","timestamp":1781813785201,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.pupt.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T20:42:37Z","timestamp":1412109757000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy"],"prefix":"10.1016","volume":"31","author":[{"given":"Federica","family":"Novelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Vergura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Camiciottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Celi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Paggiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2014.09.007_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1183\/09031936.04.00004904","article-title":"Asthma severity and medical resource utilisation","volume":"23","author":"Antonicelli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.09.007_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaci.2012.04.014","article-title":"Key findings and clinical implications from the epidemiology and natural history of asthma: outcomes and treatment Regimens (TENOR) study","volume":"130","author":"Chipps","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.pupt.2014.09.007_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2222.2005.02191.x","article-title":"Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy","volume":"35","author":"Holgate","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pupt.2014.09.007_bib4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1398-9995.2008.01723.x","article-title":"An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma","volume":"63","author":"Sullivan","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2014.09.007_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2014.09.007_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rmed.2007.08.006","article-title":"Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France","volume":"102","author":"Molimard","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib9","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.rmed.2009.05.002","article-title":"Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany","volume":"103","author":"Korn","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2500\/aap.2012.33.3527","article-title":"Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review","volume":"33","author":"Storms","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.pupt.2014.09.007_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pupt.2011.11.004","article-title":"Long-term omalizumab treatment in severe allergic asthma: the South-Eastern mediterranean real-life experience","volume":"25","author":"Tzortzaki","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.09.007_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2012.04.015","article-title":"Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma","volume":"109","author":"Lafeuille","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pupt.2014.09.007_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the real-world effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2012.09.008","article-title":"Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab","volume":"107","author":"Chen","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.12-1372","article-title":"Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: results from a large cohort of patients with severe uncontrolled asthma","volume":"143","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.09.007_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02770903.2013.790419","article-title":"Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real world study","volume":"50","author":"Barnes","year":"2013","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.pupt.2014.09.007_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00149812","article-title":"Add-on omalizumab in children with severe allergic asthma: a one year rel life survey","volume":"42","author":"Deschildre","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.09.007_bib19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.rmed.2010.04.013","article-title":"Italian real-life experience of omalizumab","volume":"104","author":"Cazzola","year":"2010","journal-title":"Respir Med"},{"issue":"Suppl.\u00a016","key":"10.1016\/j.pupt.2014.09.007_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society","volume":"6","author":"Quanjer","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.09.007_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaip.2014.02.011","article-title":"Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma","volume":"2","author":"Luskin","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pupt.2014.09.007_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-013-9463-9","article-title":"Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy","volume":"15","author":"Zhu","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.pupt.2014.09.007_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.09.007_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/02770903.2012.661008","article-title":"Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control","volume":"49","author":"Melosini","year":"2012","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.pupt.2014.09.007_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1183\/09031936.00135907","article-title":"Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma","volume":"32","author":"van Veen","year":"2008","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.pupt.2014.09.007_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.09.007_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/bmj.325.7361.411","article-title":"European community respiratory health survey. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European community respiratory health survey","volume":"325","author":"Zureik","year":"2002","journal-title":"BMJ"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:50:16Z","timestamp":1538160616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":28,"alternative-id":["S1094553914001163"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.09.007","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}